Evaluation of clinical efficacy of newly developed nanoform turmeric based dental films in the management of Chronic Periodontitis

Curcumin Nanolipomatrix Dental Films: Development, Characterisation and Clinical Evaluation for management of Chronic Periodontitis - CNL-PDF

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/11/037961

Enrollment

Registered

2021-11-11

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: CNL-PDF: CNL-PDF (gel/beads/films) Curcumin nanolipomatrix (C-SLNs) periodontal dosage form i.e CNL-PDF (gel/beads/films) to retain it at the site of infection for at least 48-72 h to e

Eligibility

Inclusion criteria

Inclusion criteria: • Patients suffering from moderate to severe chronic generalised periodontitis as defined by American Academy of Periodontology criteria, 1999 • Patients who have at least 4 sites with pocket probing depth of 6 mm or more in one or both of arches. • Patients willing for treatment.

Exclusion criteria

Exclusion criteria: • All patients suffering from known systemic diseases which could alter healing response of periodontium. • Patients who have received any periodontal treatment in 6 months before study. • History of medication (antibiotics or anti-inflammatory drugs) in 3 months before study. • Patients using medicated toothpaste or anti-bacterial mouth rinse. • Acute periodontal conditions. • Patients wearing orthodontic or other removable appliances. • Pregnant or nursing women

Design outcomes

Primary

Measure	Time frame
periodontal status clinical indicators -periodontal pocket depth,Clinical attachment level,plaque index,sulcus bleeding index, Biochemical indicators- (Interleukin-1Ã?, Interleukin-6), antiinflammatory (Interleukin-4, Interleukin-10) markers, matrix metalloproteinases (MMP-8, MMP-9), and Fibrogenic (transforming growth factor- Ã?) microbiological indicators- periodontal microflora( total cultivable counts) Timepoint: Baseline,1 month and 3 months	—

Measure

Time frame

periodontal status clinical indicators -periodontal pocket depth,Clinical attachment level,plaque index,sulcus bleeding index, Biochemical indicators- (Interleukin-1Ã?, Interleukin-6), antiinflammatory (Interleukin-4, Interleukin-10) markers, matrix metalloproteinases (MMP-8, MMP-9), and Fibrogenic (transforming growth factor- Ã?) microbiological indicators- periodontal microflora( total cultivable counts) Timepoint: Baseline,1 month and 3 months

—

Secondary

Measure	Time frame
patient centered outcomes - perceptions and attitudes via a questionnaire on VAS/VRS (visual analog scale /verbal rating scale) regarding the use of applied productTimepoint: 1 month and 3 month	—

Countries

India

Contacts

Public ContactProf Indu Pal Kaur

Dr Harvansh Singh Judge Institute of Dental Sciences and Hospital

vishakha_grover@rediffmail.com9814277780

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026